REFERENCES
1. Howlader N, Noone AM, et al (eds). SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Available from: https://seer.cancer.gov/csr/1975_2017/. [Last accessed on 4 Jan 2021].
3. Bovee JVMG, Flanagan AM, Lazar AJ, Nielsen GP, Yoshida A. Bone tumours. In: WHO classification of tumours editorial board. WHO classification of tumors: soft tissue and bone tumors 5th edition. Lyon France: International Agency for Research on Cancer; 2020. pp. 338-499.
4. Suster D, Hung YP, Nielsen GP. Differential diagnosis of cartilaginous lesions of bone. Arch Pathol Lab Med 2020;144:71-82.
5. Scheitza P, Uhl M, Hauschild O, et al. Interobserver variability in the differential diagnosis of benign bone tumors and tumor-like lesions. Rofo 2016;188:479-87.
6. Gemescu IN, Thierfelder KM, Rehnitz C, Weber MA. Imaging features of bone tumors: conventional radiographs and MR imaging correlation. Magn Reson Imaging Clin N Am 2019;27:753-67.
7. Mehta K, McBee MP, Mihal DC, England EB. Radiographic analysis of bone tumors: a systematic approach. Semin Roentgenol 2017;52:194-208.
8. Larousserie F, Kreshak J, Gambarotti M, Alberghini M, Vanel D. The importance of radiographic imaging in the microscopic assessment of bone tumors. Eur J Radiol 2013;82:2100-14.
9. Andreou D, Hardes J, Gosheger G, et al. Interdisciplinary diagnostic and treatment of bone sarcomas of the extremities and trunk. Handchir Mikrochir Plast Chir 2015;47:90-9.
10. Ferguson JL, Turner SP. Bone cancer: diagnosis and treatment principles. Am Fam Physician 2018;98:205-213.
11. Mueller C, Gambarotti M, Benini S, et al. Unlocking bone for proteomic analysis and FISH. Lab Invest 2019;99:708-21.
12. Donner LR. Cytogenetics of tumors of soft tissue and bone. Cancer Genet Cytogenet 1994;78:115-26.
13. arkkanen M, Nordling S, Böhling T, et al. Comparison of cytogenetics, interphase cytogenetics, and DNA flow cytometry in bone tumors. Cytometry 1996;26:185-91.
14. Vargas AC, Selinger C, Satgunaseelan L, et al. FISH analysis of selected soft tissue tumors: diagnostic experience in a tertiary center. Asia Pac J Clin Oncol 2019;15:38-47.
15. Tanas MR, Goldblum JR. Fluorescence in situ hybridization in the diagnosis of soft tissue neoplasms: a review. Adv Anat Pathol 2009;16:383-91.
16. Fittall MW, Mifsud W, Pillay N, et al. Recurrent rearrangements of FOS and FOSB define osteoblastoma. Nat Commun 2018;9:2150.
17. Schaefer IM, Hornick JL. Diagnostic immunohistochemistry for soft tissue and bone tumors: an update. Adv Anat Pathol 2018;25:400-12.
18. Wang GY, Thomas DG, Davis JL, et al. EWSR1-NFATC2 translocation-associated sarcoma clinicopathologic findings in a rare aggressive primary bone or soft tissue tumor. Am J Surg Pathol 2019;43:1112-22.
19. Bahrami A, Weiss SW, Montgomery E, et al. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am J Surg Pathol 2009;33:1348-54.
20. Bridge RS, Rajaram V, Dehner LP, Pfeifer JD, Perry A. Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors. Mod Pathol 2006;19:1-8.
21. Baumhoer D, Amary F, Flanagan AM. An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing. Genes Chromosomes Cancer 2019;58:88-99.
22. Szurian K, Kashofer K, Liegl-Atzwanger B. Role of next-generation sequencing as a diagnostic tool for the evaluation of bone and soft-tissue tumors. Pathobiology 2017;84:323-38.
23. Lam SW, Cleton-Jansen AM, Cleven AHG, et al. Molecular analysis of gene fusions in bone and soft tissue tumors by anchored multiplex PCR-based targeted next-generation sequencing. J Mol Diagn 2018;20:653-63.
24. Hogendoorn PC, Athanasou N, Bielack S, et al; ESMO/EUROBONET working group. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:v204-13.
25. Rubin BP, Antonescu CR, Gannon FH, et al; Members of the cancer committee, college of American pathologists. Protocol for the examination of specimens from patients with tumors of bone. Arch Pathol Lab Med 2010;134:e1-7.
26. Rubin BP, Fletcher CD, Inwards C, et al. Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumors. Arch Pathol Lab Med 2006;130:1616-29.
27. Singh VM, Salunga RC, Huang VJ, et al. Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. Ann Diagn Pathol 2013;17:322-6.
28. Choi SE, Hong SW, Yoon SO. Proposal of an appropriate decalcification method of bone marrow biopsy specimens in the era of expanding genetic molecular study. J Pathol Transl Med 2015;49:236-42.
29. Mueller C, Harpole MG, Espina V. One-step preservation and decalcification of bony tissue for molecular profiling. Methods Mol Biol 2017;1606:85-102.
30. Babic A, Loftin IR, Stanislaw S, et al. The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays. Methods 2010;52:287-300.
31. Goswami RS, Luthra R, Singh RR, et al. Identification of factors affecting the success of next-generation sequencing testing in solid tumors. Am J Clin Pathol 2016;145:222-37.
32. Nagai M, Minegishi K, Komada M, Tsuchiya M, Kameda T, Yamada S. Extraction of DNA from human embryos after long-term preservation in formalin and Bouin’s solutions. Congenit Anom (Kyoto) 2016;56:112-8.
33. Alers JC, Krijtenburg PJ, Vissers KJ, van Dekken H. Effect of bone decalcification procedures on DNA in situ hybridization and comparative genomic hybridization. EDTA is highly preferable to a routinely used acid decalcifier. J Histochem Cytochem 1999;47:703-10.
34. Raj AT, Patil S, Rao RS. A Comparison of conventional and microwave decalcification and processing of tooth and mandibular bone specimens. J Clin Diagn Res 2016;10:ZC121-6.
35. Imaizumi K, Taniguchi K, Ogawa Y. An evaluation of the effect of microwave irradiation on bone decalcification aimed to DNA extraction. Leg Med (Tokyo) 2013;15:272-7.
36. Chow DH, Zheng LZ, Tian L, Ho KS, Qin L, Guo X. Application of ultrasound accelerates the decalcification process of bone matrix without affecting histological and immunohistochemical analysis. J Orthop Translat 2019;17:112-20.
37. Mueller C, Harpole MG, Espina V. One-step preservation and decalcification of bony tissue for molecular profiling. In: Espina V, editor. Molecular profiling. New York: Springer; 2017. pp. 85-102.
38. Kapila SN, Natarajan S, Boaz K, Pandya JA, Yinti SR. Driving the mineral out faster: simple modifications of the decalcification technique. J Clin Diagn Res 2015;9:ZC93-7.
39. Lam SW, van IJzendoorn DGP, Cleton-Jansen AM, Szuhai K, Bovée JVMG. Molecular pathology of bone tumors. J Mol Diagn 2019;21:171-82.
41. Bridge JA, Cushman-Vokoun AM. Molecular diagnostics of soft tissue tumors. Arch Pathol Lab Med 2011;135:588-601.
42. Gu J, Smith JL, Dowling PK. Fluorescence in situ hybridization probe validation for clinical use. In: Wan TS, editor. Cancer cytogenetics. New York: Springer; 2017. pp. 101-18.
43. Jochmann K, Bachvarova V, Vortkamp A. Reprint of: heparan sulfate as a regulator of endochondral ossification and osteochondroma development. Matrix Biol 2014;35:239-47.
44. Bovée JV, Cleton-Jansen AM, Wuyts W, et al. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet 1999;65:689-98.
45. Santos SCL, Rizzo IMPO, Takata RI, Speck-Martins CE, Brum JM, Sollaci C. Analysis of mutations in EXT1 and EXT2 in Brazilian patients with multiple osteochondromas. Mol Genet Genomic Med 2018;6:382-92.
46. Hameetman L, David G, Yavas A, et al. Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas. J Pathol 2007;211:399-409.
47. Bell WC, Klein MJ, Pitt MJ, Siegal GP. Molecular pathology of chondroid neoplasms: part 1, benign lesions. Skeletal Radiol 2006;35:805-13.
48. Kumar A, Jain VK, Bharadwaj M, Arya RK. Ollier disease: pathogenesis, diagnosis, and management. Orthopedics 2015;38:e497-506.
49. Franceschini N, Lam SW, Cleton-Jansen AM, Bovée JVMG. What’s new in bone forming tumours of the skeleton? Virchows Arch 2020;476:147-57.
50. Amary F, Markert E, Berisha F, et al. FOS Expression in osteoid osteoma and osteoblastoma: a valuable ancillary diagnostic tool. Am J Surg Pathol 2019;43:1661-7.
51. Lam SW, Cleven AHG, Kroon HM, Briaire-de Bruijn IH, Szuhai K, Bovée JVMG. Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma. Virchows Arch 2020;476:455-63.
52. Panagopoulos I, Gorunova L, Lobmaier I, et al.
53. Giannico G, Holt GE, Homlar KC, Johnson J, Pinnt J, Bridge JA. Osteoblastoma characterized by a three-way translocation: report of a case and review of the literature. Cancer Genet Cytogenet 2009;195:168-71.
54. Saba KH, Cornmark L, Hofvander J, et al. Loss of NF2 defines a genetic subgroup of non-FOS-rearranged osteoblastoma. J Pathol Clin Res 2020;6:231-7.
55. Nord KH, Nilsson J, Arbajian E, et al. Recurrent chromosome 22 deletions in osteoblastoma affect inhibitors of the Wnt/beta-catenin signaling pathway. PLoS One 2013;8:e80725.
56. Bovée JV, Hogendoorn PC. Non-ossifying fibroma: A RAS-MAPK driven benign bone neoplasm. J Pathol 2019;248:127-30.
57. Bridge JA, Swarts SJ, Buresh C, et al. Trisomies 8 and 20 characterize a subgroup of benign fibrous lesions arising in both soft tissue and bone. Am J Pathol 1999;154:729-33.
58. E Horvai A, C Jordan R. Fibro-osseous lesions of the craniofacial bones: β-catenin immunohistochemical analysis and CTNNB1 and APC mutation analysis. Head Neck Pathol 2014;8:291-7.
59. Trombetta D, Macchia G, Mandahl N, Nord KH, Mertens F. Molecular genetic characterization of the 11q13 breakpoint in a desmoplastic fibroma of bone. Cancer Genet 2012;205:410-3.
60. Song W, van den Berg E, Kwee TC, et al. Low-grade central fibroblastic osteosarcoma may be differentiated from its mimicker desmoplastic fibroma by genetic analysis. Clin Sarcoma Res 2018;8:16.
61. Behjati S, Tarpey PS, Presneau N, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 2013;45:1479-82.
62. Smith LT, Mayerson J, Nowak NJ, et al. 20q11.1 amplification in giant-cell tumor of bone: Array CGH, FISH, and association with outcome. Genes Chromosomes Cancer 2006;45:957-66.
63. Kato Kaneko M, Liu X, Oki H, et al. Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone. Cancer Sci 2014;105:744-8.
64. Suster DI, Kurzawa P, Neyaz A, et al. Chondroblastoma expresses RANKL by RNA in situ hybridization and may respond to denosumab therapy. Am J Surg Pathol 2020;44:1581-90.
65. Althof PA, Ohmori K, Zhou M, et al. Cytogenetic and molecular cytogenetic findings in 43 aneurysmal bone cysts: aberrations of 17p mapped to 17p13.2 by fluorescence in situ hybridization. Mod Pathol 2004;17:518-25.
66. Oliveira AM, Chou MM. USP6-induced neoplasms: the biologic spectrum of aneurysmal bone cyst and nodular fasciitis. Hum Pathol 2014;45:1-11.
67. Blackburn PR, Davila JI, Jackson RA, et al. RNA sequencing identifies a novel USP9X-USP6 promoter swap gene fusion in a primary aneurysmal bone cyst. Genes Chromosomes Cancer 2019;58:589-94.
68. Guseva NV, Jaber O, Tanas MR, et al. Anchored multiplex PCR for targeted next-generation sequencing reveals recurrent and novel USP6 fusions and upregulation of USP6 expression in aneurysmal bone cyst. Genes Chromosomes Cancer 2017;56:266-77.
69. Šekoranja D, Boštjančič E, Salapura V, Mavčič B, Pižem J. Primary aneurysmal bone cyst with a novel SPARC-USP6 translocation identified by next-generation sequencing. Cancer Genet 2018;228-229:12-6.
70. Šekoranja D, Zupan A, Mavčič B, et al. Novel ASAP1-USP6, FAT1-USP6, SAR1A-USP6, and TNC-USP6 fusions in primary aneurysmal bone cyst. Genes Chromosomes Cancer 2020;59:357-65.
71. Milne P, Bigley V, Bacon CM, et al. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood 2017;130:167-75.
72. Postini AM, Andreacchio A, Boffano M, Pagano M, Brach Del Prever A, Fagioli F. Langerhans cell histiocytosis of bone in children: a long-term retrospective study. J Pediatr Orthop B 2012;21:457-62.
73. Maria Postini A, del Prever AB, Pagano M, et al. Langerhans cell histiocytosis: 40 years’ experience. J Pediatr Hematol Oncol 2012;34:353-8.
74. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116:1919-23.
75. Papo M, Cohen-Aubart F, Trefond L, et al. Systemic histiocytosis (langerhans cell histiocytosis, erdheim-chester disease, destombes-rosai-dorfman disease): from oncogenic mutations to inflammatory disorders. Curr Oncol Rep 2019;21:62.
76. Jour G, Oultache A, Sadowska J, et al. GNAS mutations in fibrous dysplasia: a comparative study of standard sequencing and locked nucleic acid PCR sequencing on decalcified and nondecalcified formalin-fixed paraffin-embedded tissues. Appl Immunohistochem Mol Morphol 2016;24:660-7.
78. Pereira TDSF, Gomes CC, Brennan PA, Fonseca FP, Gomez RS. Fibrous dysplasia of the jaws: integrating molecular pathogenesis with clinical, radiological, and histopathological features. J Oral Pathol Med 2019;48:3-9.
80. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011;224:334-43.
81. Nicolle R, Ayadi M, Gomez-Brouchet A, et al. Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression. Nat Commun 2019;10:4622.
82. Parker SJ, Metallo CM. Metabolic consequences of oncogenic IDH mutations. Pharmacol Ther 2015;152:54-62.
83. He X, Pang ZG, Zhang XL, et al. Consistent amplification of FRS2 and MDM2 in low-grade osteosarcoma: a genetic study of 22 cases with clinicopathologic analysis. Am J Surg Pathol 2018;42:1143-55.
84. Limbach AL, Lingen MW, McElherne J, et al. The utility of MDM2 and CDK4 immunohistochemistry and MDM2 FISH in craniofacial osteosarcoma. Head Neck Pathol 2020;14:889-98.
85. Righi A, Gambarotti M, Benini S, et al. MDM2 and CDK4 expression in periosteal osteosarcoma. Hum Pathol 2015;46:549-53.
86. Chen PC, Yen CC, Hung GY, Pan CC, Chen WM. Gene amplification and tumor grading in parosteal osteosarcoma. J Chin Med Assoc 2019;82:889-94.
87. Olivos DJ 3rd, Perrien DS, Hooker A, et al. The proto-oncogene function of Mdm2 in bone. J Cell Biochem 2018;119:8830-40.
88. Shing DC, McMullan DJ, Roberts P, et al. FUS/ERG gene fusions in Ewing’s tumors. Cancer Res 2003;63:4568-4576.
89. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5.
90. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994;331:294-9.
91. Watson S, Perrin V, Guillemot D, et al. Transcriptomic definition of molecular subgroups of small round cell sarcomas. J Pathol 2018;245:29-40.
93. Folpe AL. Phosphaturic mesenchymal tumors: a review and update. Semin Diagn Pathol 2019;36:260-8.
94. Lee JC, Su SY, Changou CA, et al. Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol 2016;29:1335-46.
95. Lee JC, Jeng YM, Su SY, et al. Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J Pathol 2015;235:539-45.
96. Graham RP, Hodge JC, Folpe AL, et al. A cytogenetic analysis of 2 cases of phosphaturic mesenchymal tumor of mixed connective tissue type. Hum Pathol 2012;43:1334-8.
97. Xu J, Li D, Xie L, Tang S, Guo W. Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years. PLoS One 2015;10:e0122216.
98. Wang L, Motoi T, Khanin R, et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer 2012;51:127-39.
99. Naumann S, Krallman PA, Unni KK, Fidler ME, Neff JR, Bridge JA. Translocation der(13;21)(q10;q10) in skeletal and extraskeletal mesenchymal chondrosarcoma. Mod Pathol 2002;15:572-6.
100. Nord KH, Lilljebjörn H, Vezzi F, et al. GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoid fibroma. Nat Genet 2014;46:474-7.
101. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 2003;145:1-30.
103. Lin YH, Jewell BE, Gingold J, et al. Osteosarcoma: molecular pathogenesis and iPSC modeling. Trends Mol Med 2017;23:737-55.
104. Li CJ, Cong Y, Liu XZ, et al. The progress of molecular diagnostics of osteosarcoma. Front Biosci (Landmark Ed) 2016;21:20-30.
105. Negri GL, Grande BM, Delaidelli A, et al. Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma. J Pathol 2019;249:319-31.
106. Lin Y, Seger N, Chen Y, et al. hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality. Mod Pathol 2018;31:1834-41.
107. van Oosterwijk JG, de Jong D, van Ruler MA, et al. Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone. BMC Cancer 2012;12:375.
108. Zhu GG, Nafa K, Agaram N, et al. Genomic profiling identifies association of
109. Sakamoto A. The molecular pathogenesis of dedifferentiated chondrosarcoma. Indian J Orthop 2014;48:262-5.
110. Swarts SJ, Neff JR, Johansson SL, Bridge JA. Cytogenetic analysis of dedifferentiated chondrosarcoma. Cancer Genet Cytogenet 1996;89:49-51.
111. Makise N, Sekimizu M, Konishi E, et al. H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features. Mod Pathol 2019;32:435-45.
112. Ali NM, Niada S, Morris MR, et al. Comprehensive molecular characterization of adamantinoma and OFD-like adamantinoma bone tumors. Am J Surg Pathol 2019;43:965-74.
113. Gleason BC, Liegl-Atzwanger B, Kozakewich HP, et al. Osteofibrous dysplasia and adamantinoma in children and adolescents: a clinicopathologic reappraisal. Am J Surg Pathol 2008;32:363-76.
114. Taylor RM, Kashima TG, Ferguson DJ, Szuhai K, Hogendoorn PC, Athanasou NA. Analysis of stromal cells in osteofibrous dysplasia and adamantinoma of long bones. Mod Pathol 2012;25:56-64.
115. Kanamori M, Antonescu CR, Scott M, et al. Extra copies of chromosomes 7, 8, 12, 19, and 21 are recurrent in adamantinoma. J Mol Diagn 2001;3:16-21.
116. Hazelbag HM, Wessels JW, Mollevangers P, van den Berg E, Molenaar WM, Hogendoorn PC. Cytogenetic analysis of adamantinoma of long bones: further indications for a common histogenesis with osteofibrous dysplasia. Cancer Genet Cytogenet 1997;97:5-11.
117. Shih AR, Chebib I, Deshpande V, Dickson BC, Iafrate AJ, Nielsen GP. Molecular characteristics of poorly differentiated chordoma. Genes Chromosomes Cancer 2019;58:804-8.
118. Scheil-Bertram S, Kappler R, von Baer A, et al. Molecular profiling of chordoma. Int J Oncol 2014;44:1041-55.
119. Gil Z, Fliss DM. Cytogenetic analysis of skull base tumors: where do we stand? Curr Opin Otolaryngol Head Neck Surg 2012;20:130-6.
120. Gil Z, Fliss DM, Voskoboinik N, et al. Cytogenetic analysis of three variants of clival chordoma. Cancer Genet Cytogenet 2004;154:124-30.
121. Scheil S, Brüderlein S, Liehr T, et al. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 2001;32:203-11.
122. Brohl AS, Kahen E, Yoder SJ, Teer JK, Reed DR. The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation. Sci Rep 2017;7:14992.
123. Wesche WA, Khare V, Rao BN, Bowman LC, Parham DM. Malignant peripheral nerve sheath tumor of bone in children and adolescents. Pediatr Dev Pathol 1999;2:159-67.
124. Liu WJ, Zhang S, Liu JX, Shao ZW. Intraosseous malignant peripheral nerve sheath tumor of 2 consecutive lumbar vertebrae: a case report and literature review. World Neurosurg 2019;130:459-66.
125. Davila A, Conrad EU, Ayala GE, Beckmann NM. Intraosseous malignant peripheral nerve sheath tumor of the sacrum in a patient with neurofibromatosis type I. Radiol Case Rep 2019;14:880-4.
126. Demicco EG, Wang WL, Madewell JE, et al. Osseous myxochondroid sarcoma: a detailed study of 5 cases of extraskeletal myxoid chondrosarcoma of the bone. Am J Surg Pathol 2013;37:752-62.
127. Finos L, Righi A, Frisoni T, et al. Primary extraskeletal myxoid chondrosarcoma of bone: Report of three cases and review of the literature. Pathol Res Pract 2017;213:461-6.
128. Hisaoka M, Hashimoto H. Extraskeletal myxoid chondrosarcoma: updated clinicopathological and molecular genetic characteristics. Pathol Int 2005;55:453-63.
129. Tran H, Shillingford N, Thomas S, Hammoudeh J, Zhou S. Primary epithelioid sarcoma of the zygomatic bone. Pediatr Dev Pathol 2019;22:252-7.
130. Raoux D, Péoc’h M, Pedeutour F, Vaunois B, Decouvelaere AV, Folpe AL. Primary epithelioid sarcoma of bone: report of a unique case, with immunohistochemical and fluorescent in situ hybridization confirmation of INI1 deletion. Am J Surg Pathol 2009;33:954-8.
131. Wojcik JB, Bellizzi AM, Dal Cin P, et al. Primary sclerosing epithelioid fibrosarcoma of bone: analysis of a series. Am J Surg Pathol 2014;38:1538-44.
132. Tsuda Y, Dickson BC, Dry SM, et al. Clinical and molecular characterization of primary sclerosing epithelioid fibrosarcoma of bone and review of the literature. Genes Chromosomes Cancer 2020;59:217-24.
133. Kosemehmetoglu K, Ardic F, Kilpatrick SE, Aydingoz U, Sumathi VP, Michal M. Sclerosing epithelioid fibrosarcoma of bone: morphological, immunophenotypical, and molecular findings of 9 cases. Virchows Arch 2020; doi: 10.1007/s00428-020-02953-y.
134. Kalil RK. Liposarcoma of bone. In: Santini-Araujo E, Kalil R, Bertoni F, Park YK, editors. Tumors and tumor-like lesions of bone. London: Springer; 2015. pp. 569-573.
135. Tiemeier GL, Brown JM, Pratap SE, et al. Pleomorphic liposarcoma of bone: a rare primary malignant bone tumour. Clin Sarcoma Res 2018;8:2.
136. Zhang S, Wang XQ. Primary dedifferentiated liposarcoma of the femur presenting with malignant fibrous histiocytoma: a case report and review of the literature. Oncol Lett 2014;8:663-6.
137. Rovlias A, Balanika A, Nomikos A, Melissaris S. Primary myxoid liposarcoma of the upper thoracic spine in an elderly patient. J Neurosci Rural Pract 2017;8:S120-2.
138. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet Cytogenet 2004;155:1-24.
139. Park YK, Unni KK, Kim YW, et al. Primary alveolar soft part sarcoma of bone. Histopathology 1999;35:411-7.
141. Kawamura-Saito M, Yamazaki Y, Kaneko K, et al. Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum Mol Genet 2006;15:2125-37.
142. Pižem J, Šekoranja D, Zupan A, et al. FUS-NFATC2 or EWSR1-NFATC2 fusions are present in a large proportion of simple bone cysts. Am J Surg Pathol 2020;44:1623-34.
143. Pierron G, Tirode F, Lucchesi C, et al. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet 2012;44:461-6.
144. Szuhai K, Ijszenga M, de Jong D, Karseladze A, Tanke HJ, Hogendoorn PC. The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res 2009;15:2259-68.
145. Davicioni E, Anderson MJ, Finckenstein FG, et al. Molecular classification of rhabdomyosarcoma - genotypic and phenotypic determinants of diagnosis: a report from the Children’s Oncology Group. Am J Pathol 2009;174:550-64.
146. Balogh P, Bánusz R, Csóka M, Váradi Z, Varga E, Sápi Z. Primary alveolar rhabdomyosarcoma of the bone: two cases and review of the literature. Diagn Pathol 2016;11:99.
147. Agaram NP, Zhang L, Sung YS, et al. Expanding the spectrum of intraosseous rhabdomyosarcoma: correlation between 2 distinct gene fusions and phenotype. Am J Surg Pathol 2019;43:695-702.
148. Anderson J, Gordon A, McManus A, Shipley J, Pritchard-Jones K. Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia 1999;1:340-8.
149. Wang GY, Lucas DR. Primary leiomyosarcoma of bone: review and update. Arch Pathol Lab Med 2019;143:1332-7.
150. Wirbel RJ, Verelst S, Hanselmann R, Remberger K, Kubale R, Mutschler WE. Primary leiomyosarcoma of bone: clinicopathologic, immunohistochemical, and molecular biologic aspects. Ann Surg Oncol 1998;5:635-41.
151. Verbeke SL, Fletcher CD, Alberghini M, et al. A reappraisal of hemangiopericytoma of bone; analysis of cases reclassified as synovial sarcoma and solitary fibrous tumor of bone. Am J Surg Pathol 2010;34:777-83.
152. Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 2013;45:180-5.
153. Ge XH, Liao JS, Choo RJ, Yan JC, Zhang JF. Solitary fibrous tumor of the ilium: a case report. Medicine (Baltimore) 2017;96:e9355.
154. Horvai A, Dashti NK, Rubin BP, et al. Genetic and molecular reappraisal of spindle cell adamantinoma of bone reveals a small subset of misclassified intraosseous synovial sarcoma. Mod Pathol 2019;32:231-41.
155. Fujibuchi T, Miyawaki J, Kidani T, et al. Intraosseous synovial sarcoma of the distal ulna: a case report and review of the literature. BMC Cancer 2019;19:116.
156. Shah WU, Shujaat SD, Ullah N, Mansoor S. Synovial sarcoma of cervicodorsal spine: a case report. J Pak Med Assoc 2018;68:1100-1104.
157. Kim J, Lee SH, Choi YL, Bae GE, Kim ES, Eoh W. Synovial sarcoma of the spine: a case involving paraspinal muscle with extensive calcification and the surgical consideration in treatment. Eur Spine J 2014;23:27-31.
158. Verma A, Rekhi B. Myoepithelial tumor of soft tissue and bone: a current perspective. Histol Histopathol 2017;32:861-77.
159. Rekhi B, Amare P, Gulia A, et al. Primary intraosseous myoepithelioma arising in the iliac bone and displaying trisomies of 11, 15, 17 with del (16q) and del (22q11)--A rare case report with review of literature. Pathol Res Pract 2011;207:780-5.
160. Rekhi B, Joshi S, Panchwagh Y, et al. Clinicopathological features of five unusual cases of intraosseous myoepithelial carcinomas, mimicking conventional primary bone tumours, including EWSR1 rearrangement in one case. APMIS 2016;124:278-90.
161. Suurmeijer AJH, Dickson BC, Swanson D, et al. A morphologic and molecular reappraisal of myoepithelial tumors of soft tissue, bone, and viscera with EWSR1 and FUS gene rearrangements. Genes Chromosomes Cancer 2020;59:348-56.
162. Yamaguchi S, Yamazaki Y, Ishikawa Y, Kawaguchi N, Mukai H, Nakamura T. EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12). Genes Chromosomes Cancer 2005;43:217-22.
163. Xian J, Righi A, Vanel D, Baldini N, Errani C. Epithelioid hemangioma of bone: a unique case with multifocal metachronous bone lesions. J Clin Orthop Trauma 2019;10:1068-72.
164. van IJzendoorn DG, de Jong D, Romagosa C, et al. Fusion events lead to truncation of FOS in epithelioid hemangioma of bone. Genes Chromosomes Cancer 2015;54:565-74.
165. Huang SC, Zhang L, Sung YS, et al. Frequent FOS gene rearrangements in epithelioid hemangioma: a molecular study of 58 cases with morphologic reappraisal. Am J Surg Pathol 2015;39:1313-21.
166. Verbeke SL, Bovée JV. Primary vascular tumors of bone: a spectrum of entities? Int J Clin Exp Pathol 2011;4:541-51.
167. Xu YJ, Chen WX, Cheng H, Lin ZY. Epithelioid hemangioendothelioma of the bone: a case report with findings of bone scintigraphy. Medicine (Baltimore) 2019;98:e15546.
168. Otani S, Nakayama R, Sekita T, et al. Pseudomyogenic hemangioendothelioma of bone treated with denosumab: a case report. BMC Cancer 2019;19:872.
169. Inyang A, Mertens F, Puls F, et al. Primary pseudomyogenic hemangioendothelioma of bone. Am J Surg Pathol 2016;40:587-98.
170. Walther C, Tayebwa J, Lilljebjörn H, et al. A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma. J Pathol 2014;232:534-40.
171. Baliaka A, Balis G, Michalopoulou-Manoloutsiou E, Papanikolaou A, Nikolaidou A. Primary angiosarcoma of bone. A case report. Hippokratia 2013;17:180-2.
172. Palmerini E, Leithner A, Windhager R, et al. Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS). Sci Rep 2020;10:10853.
173. Deshpande V, Rosenberg AE, O’Connell JX, Nielsen GP. Epithelioid angiosarcoma of the bone: a series of 10 cases. Am J Surg Pathol 2003;27:709-16.
174. Huang SC, Zhang L, Sung YS, et al. Recurrent CIC gene abnormalities in Angiosarcomas: a molecular study of 120 cases with concurrent investigation of PLCG1, KDR, MYC, and FLT4 gene alterations. Am J Surg Pathol 2016;40:645-55.
175. Ali NM, Niada S, Brini AT, et al. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone. J Pathol 2019;247:166-76.
176. Li XN, Zhang ZK, Latif M, Chen W, Cui JL, Peng ZG. Synovium as a widespread pathway to the adjacent joint in undifferentiated high-grade pleomorphic sarcoma of the tibia: a case report. Medicine (Baltimore) 2018;97:e9870.
177. Zhou N, Schäfer R, Li T, Fang MY, Liu LY. A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report. BMC Cancer 2018;18:842.
178. Cerejeira A, Gomes N, Costa-Silva M, Moreira E, Azevedo F. Undifferentiated pleomorphic sarcoma presenting as an exophytic pedunculated tumor on the left scapula. Dermatol Online J 2019;25:13030/qt738094fs.
179. Garces S, Medeiros LJ, Patel KP, et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol 2017;30:1367-77.
180. Mosheimer BA, Oppl B, Zandieh S, et al. Bone involvement in rosai-dorfman disease (RDD): a case report and systematic literature review. Curr Rheumatol Rep 2017;19:29.
181. Mavrogenis AF, Igoumenou VG, Antoniadou T, et al. Rare diseases of bone: Erdheim-Chester and Rosai-Dorfman non-Langerhans cell histiocytoses. EFORT Open Rev 2018;3:381-90.
182. Ross AB, Davis KW, Buehler D, Chan BY. Primary rosai-dorfman disease of bone: a report of two cases. Case Rep Radiol 2019;2019:1720131.
